Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679644 | 0.73 | TSHR (0.30) | TSHRMAPK1 | |
| SCHEMBL3799159 | 0.60 | BRD4 (0.43) | KDM4EHTTTDP1 | |
| SCHEMBL3797366 | 0.60 | BRD4 (0.46) | TSHRHTTTDP1 | |
| SCHEMBL680040 | 0.60 | — | — | |
| SCHEMBL679853 | 0.59 | ALDH1A1 (0.31) | — | |
| SCHEMBL3799033 | 0.58 | — | — | |
| SCHEMBL686685 | 0.58 | ALDH1A1 (0.33) | — | |
| SCHEMBL14222294 | 0.58 | IDO1 (0.38) | KDM4E | |
| Myrtenol SCHEMBL15442802 | 0.57 | TSHR (0.54) | TSHRKDM4EHTTTDP1MAPK1 | |
| Myrtenol SCHEMBL24281940 | 0.57 | TSHR (0.58) | TSHRKDM4EHTTTDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | B2M, MRPL21, RCE1 | TSHR 3794/4885KDM4E 2265/4885HTT 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.